Abstract
Chemopreventive strategies for colorectal cancer (CRC) have been extensively studied to prevent the recurrence of adenomas and/or delay their development in the gastrointestinal tract. The non-steroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors have been proven as promising and the most attractive candidates for CRC clinical chemoprevention. The preventive efficacy of these agents is supported by a large number of animal and epidemiological studies which have clearly demonstrated that NSAID consumption prevents adenoma formation and decreases the incidence of, and mortality from CRC. On the basis of these studies, aspirin chemoprevention may be effective in preventing CRC within the general population, while aspirin and celecoxib may be effective in preventing adenomas in patients after polypectomy. Nevertheless, the consumption of NSAID and COX-2 inhibitors is not toxic free. Well-known serious adverse events to the gastrointestinal, renal and cardiovascular systems have been reported. These reports have led to some promising studies related to the use of lower doses and in combination with other chemopreventive agents and shown efficacy. In the intriguing jigsaw puzzle of cancer prevention, we now have a definite positive answer for the basic question “if”, but several other parts of the equation-proper patient selection, the ultimate drug, optimal dosage and duration are still missing.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Agarwal B, Rao CV, Bhendwal S et al (1999) Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gastroenterology 117(4):838–847
Arber N, Eagle CJ, Spicak J et al (2006) PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 55(9):885–895
Arber N (2008) Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev 17(8):1852–1857
Arber N, Levin B (2008) Chemoprevention of colorectal neoplasia; the potential for personalized medicine. Gastroenterology 134(4):1224–1237
Arber N, Spicak J, Rácz I et al (2011) Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol 106(6):1135–1146
Baron JA, Sandler RS, Bresalier RS et al (2006) Approve Trial Investigators. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 131(6):1674–1682
Barry EL, Sansbury LB, Grau MV et al (2009) Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence–data from a randomized clinical trial. Cancer Epidemiol Biomarkers Prev 18(10):2726–2733
Bennett A, Del Tacca M. In: Proceedings prostaglandins in human colonic carcinoma Gut 1975; 16(5):409
Bertagnolli MM, Eagle CJ, Zauber AG et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873–884
Bertagnolli MM (2007) Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol 8:439–443
Bertagnolli MM, Eagle CJ, Zauber AG et al (2009) Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial Cancer Prev Res 2(4):310–321
Bond J, Graham N, Padovani A et al (2010) Screening for cognitive impairment. Alzheimer’s disease and other dementias: opinions of European caregivers, payors, physicians and the general public J Nutr Health Aging 14:558–562
Bresalier RS, Sandler RS, Quan H et al (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092–1102
Chan AT, Ogino S, Fuchs CS (2007) Aspirin and the risk of colorectal cancer in relation to the expression of COX-2 N Engl J Med 356(21):2131–2142
Chandrasekharan NV (2002) D. H. COX-3, a cyclooxygenase-1 varient inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 99(21):13926–13931
Elder DJ, Baker JA, Banu NA et al (2002) Human colorectal adenomas demonstrate a size-dependent increase in epithelial cyclooxygenase-2 expression. J Pathol 198(4):428–434
Etminan M, Gill S, Samil A (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer’s disease: systematic review and meta-analysis of observational studies. BMJ 327:128
Greenhough A, Smartt HJ, Moore AE et al (2009) The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30(3):377–386
Grover JK, Yadav S, Vats V et al (2003) Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int J Colorectal Dis 18(4):279–291
Jaffe BM (1974) Prostaglandins and cancer: an update. Prostaglandins 6(6):453–461
Lagaos SW (2006) Time-to-event analyses for long-term treatments—the APPROVe trial. N Engl J Med 355(2):113–117
Lin HJ, Lakkides KM, Keku TO et al (2002) Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 11(11):1305–1315
Macarthur M, Sharp L, Hold GL et al (2005) The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 14(7):1613–1618
Mamdani M, Juurlink DN, Lee DS et al (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363(9423):1751–1756
Meyskens FL Jr, McLaren CE, Pelot D, et al (2008) Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled double-blind trial. Cancer Prev Res (Phila) 1(1):32–38
Pereira C, Pimentel-Nunes P, Brandão C et al (2010) COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention. Eur J Gastroenterol Hepatol 22(5):607–613
Rao CV, Reddy BS (2004) NSAIDs and chemoprevention Curr Cancer Drug Targets 4(1):29–42
Reddy BS, Wang CX, Kong AN et al (2006) Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66(8):4542–4546
Sheehan KM, Sheahan K, O’Donoghue DP et al (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282(13):1254–1257
Sinicrope FA (2006) Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog 45(6):447–454
Tuynman JB (2004) P. M. COX-2 inhibition as a tool to treat and prevent colon cancer. Crit Rev Oncol Hematol 52(2):81–101
Ulrich CM, Bigler J (2006) Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics Nat Rev Cancer 6(2):130–140
Zell JA, Pelot D, Chen WP, et al (2009) Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas Cancer Prev Res (Phila) 2(3):209–212
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Kraus, S., Naumov, I., Arber, N. (2013). COX-2 Active Agents in the Chemoprevention of Colorectal Cancer. In: Chan, A., Detering, E. (eds) Prospects for Chemoprevention of Colorectal Neoplasia. Recent Results in Cancer Research, vol 191. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-30331-9_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-30331-9_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-30330-2
Online ISBN: 978-3-642-30331-9
eBook Packages: MedicineMedicine (R0)